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OBJECTIVE— Insulin resistance may be a risk factor for diabetic microangiopathy, which
may have a familial component. We carried out a family-based study to determine which
components of the insulin resistance syndrome are associated with diabetic retinopathy and
nephropathy in type 1 diabetes.
RESEARCH DESIGN AND METHODS— The Genesis France-Belgium Study is a
multicenter binational study designed to investigate the genetic factors involved in the micro-
vascular complications of type 1 diabetes using a family-based design. Probands were type 1
diabetic patients with diabetic retinopathy (classified as background, preproliferative, or prolif-
erative) and possibly diabetic nephropathy (absent, incipient, established, or advanced). The
insulin resistance score of their first-degree relatives was calculated according to their BMI and
history of arterial hypertension, lipid disorders, and type 2 diabetes.
RESULTS— The insulin resistance score of relatives was positively correlated with the albu-
min excretion rate (P  0.0009) and fasting plasma glucose (P  0.0003) and HbA1c (P 
0.0001) concentrations. This score was higher in the relatives of probands with than in those
without diabetic nephropathy (P 0.0370). Similarly, it was higher in relatives of subjects with
proliferative diabetic retinopathy than in those of probands without, even after controlling for
subjects with versus without diabetic nephropathy (P 0.0379). However, the components of
the insulin resistance score in relatives differed according to the severity of diabetic retinopathy
or nephropathy in the probands. Obesity and history of arterial hypertension were most common
in relatives of probands with proliferative dia-
betic retinopathy, whereas obesity and history of
lipid disorders were most common in the rela-
tives of probands with diabetic nephropathy.
CONCLUSIONS— Familial insulin resis-
tance segregates with diabetic complications:
lipid disorders and obesity segregate with di-
abetic nephropathy, whereas arterial hyper-
tension and obesity segregate with diabetic
retinopathy.
Diabetes Care 27:2661–2668, 2004
M icrovascular complications are thehallmark of type 1 diabetes. Dia-betic retinopathy is the most com-
mon sight-threatening disease in
developed countries (1). Diabetic ne-
phropathy is associated with increased
mortality and cardiovascular morbidity
(2,3).
Epidemiological studies (4,5) have
revealed a familial predisposition to dia-
betic nephropathy. Parental predisposi-
tion to cardiovascular morbidity and
mortality (6,7), arterial hypertension (8–
10), and kidney disease (11,12) is likely
to play a role in this predisposition to di-
abetic nephropathy. However, the exact
determinants are still poorly understood.
Familial predisposition to retinopathy
also has been evidenced in diabetes (13),
particularly to proliferative retinopathy in
type 1 diabetic patients (14). Family-
based studies make it possible to identify
clinical features in relatives that could be
altered by the disease in patients. There-
fore, they are a valuable tool for testing
pathophysiological hypotheses.
According to the definitions of the
National Cholesterol Education Program
(15) and the World Health Organization
(WHO) (16), insulin resistance syndrome
is characterized by a cluster of cardiovas-
cular risk factors that can be easily as-
sessed in clinical practice. These factors
include hypertension (17), dyslipidemia
(18), familial history of type 2 diabetes
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(19), and obesity (20,21). Interestingly,
these are also risk factors for the develop-
ment and progression of microvascular
complications, suggesting that insulin re-
sistance plays a key role in microvascular
complications (22).
Insulin resistance is a key feature of
type 2 diabetes (23). However, according
to longitudinal prospective studies
(24,25), it is also a risk factor for diabetic
retinopathy and nephropathy in type 1
diabetic patients. Only small studies (26–
28) have tried to determine whether fa-
milial insulin resistance is a key
determinant of familial predisposition to
diabetic renal complications, but none
have examined the link between familial
insulin resistance and diabetic retinopa-
thy. We analyzed whether insulin resis-
tance in first-degree relatives of type 1
diabetic patients is associated with vari-
ous stages of diabetic retinopathy and ne-
phropathy in a large family-based study.
RESEARCH DESIGN AND
METHODS— The Genesis France-
Belgium Study is a prospective, multi-
center, family-based study, the main aim
of which is to study the genetic determi-
nants of diabetic nephropathy and reti-
nopathy in type 1 diabetes. Between
November 1998 and December 2000,
662 subjects with type 1 diabetes (defined
by age at onset 35 years, with initial
ketosis and requirement for permanent
insulin treatment within 1 year of diagno-
sis) were recruited in 38 diabetes or ne-
phrology clinics in France and Belgium.
The present article is limited to the the
275 type 1 diabetic patients for which fa-
milial data are available (referred to as
probands). Patients were recruited ac-
cording to their renal status and family
structure. Probands classified as positive
for diabetic nephropathy had type 1 dia-
betes for 5 years, background or more
severe diabetic retinopathy (see classifica-
tion below), and incipient, established, or
advanced nephropathy (see classification
below). Probands classified as negative
for diabetic nephropathy had type 1 dia-
betes for 20 years, with background or
more severe retinopathy but without kid-
ney disease (see classification below). Pro-
bands (diabetic nephropathy–positive
case subjects and –negative control sub-
jects) were only included if their two par-
ents were alive (trio families) or if one
parent and at least one sibling were alive
(pseudotrio families). Some complex
families were also recruited. They con-
sisted of at least three family members,
including one index not considered sim-
ply as trio or pseudotrio (e.g., one diabetic
sibpair plus both parents). The study de-
sign was approved by the ethics commit-
tee of Angers University Hospital. All
study participants (patients and relatives)
gave written informed consent.
Type 1 diabetic patients were exam-
ined by their diabetes specialist in their
diabetes clinic (or by their nephrologist if
they were being treated for renal failure),
and their first-degree relatives were exam-
ined by their regular physician. History of
arterial hypertension, dyslipidemia, myo-
cardial infaction, stroke, heart failure, and
end-stage renal disorder was recorded.
Blood pressure was determined using
a mercury sphygmomanometer after a
5-min rest in the sitting position. Body
weight and height were measured in light
clothes without shoes. A resting electro-
cardiogram was recorded for all type 1
diabetic patients. During medical visits,
10 ml urine was collected for albumin ex-
cretion rate (AER) determination and 38




Nephropathy was staged for probands by
an independent adjudication committee,
as previously described (29), using the
patient’s medical records and the three
highest urinary AERs recorded in the pa-
tient’s records during the previous 10
years as well as the antihypertensive treat-
ment and the last plasma creatinine mea-
surement. No nephropathy was classified
as persistent normoalbuminuria (median
of three urinary AER samples20 mg/l or
20 g/min or 30 mg/24 h) without anti-
hypertensive treatment, including ACE
inhibitors or angiotensin-II blockers. In-
cipient nephropathy was classified as per-
sistent microalbuminuria (median of
three urinary AER samples 20–200 mg/l
or 20–200 g/min or 30–300 mg/24 h).
Established nephropathy was classified as
persistent proteinuria (median of three
urinary AER samples 200 mg/l or 200
g/min or 300 mg/24 h) with plasma cre-
atinine 150 mol/l. Advanced ne-
phropathy was classified as increased
AER and plasma creatinine 150 mol/l
and/or renal replacement therapy. Case
subjects had nephropathy (incipient, es-
tablished, or advanced), and control sub-
jects did not have nephropathy.
Classification of diabetic
retinopathy
Retinopathy was staged by an indepen-
dent adjudication committee according to
Kohner’s (30) classification, using the
data obtained by direct funduscopy after
pupil dilatation and/or fluorescein an-
giography. Stage 1 diabetic retinopathy
(background retinopathy) was deter-
mined by three or more microaneurysms
with or without hard exsudates and/or
hemorrhages, stage 2 (preproliferative
retinopathy) by intraretinal microvascu-
lar abnormalities and/or cotton wood ex-
sudates, and stage 3 (proliferative
retinopathy) by new vessels and/or past or
present laser panphotocoagulation.
Insulin resistance score
Insulin resistance was assessed in relatives
according to WHO recommendations
(16). Hypertension, personal history of
lipid disorders, personal history of type 2
diabetes, and obesity were considered.
The insulin resistance score was calcu-
lated as follows.
Hypertension. Relatives received 0
points if they did not have a history of
hypertension and 1 point if they did have
a history of hypertension (systolic [SBP]/
diastolic blood pressure140/80 mmHg
at physical examination and/or antihyper-
tensive treatment) (31).
Lipid disorders. Relatives received 0
points if they did not have a history of
dyslipidemia and 1 point if they had a
lipid disorder (total cholesterol 6
mmol/l and/or fasting triglycerides 2.3
mmol/l) or were on hypolipidemic treat-
ment.
Type 2 diabetes. Relatives received 1
point if they had a personal history of type
2 diabetes (23) (regardless of diabetes
treatment) and 0 points otherwise.
Obesity. Relatives received 0 points if
their weight was normal (BMI 25 kg/
m2), 0.5 points if they were overweight
(BMI 25–29.9 kg/m2), and 1 point if they
were obese (BMI 30 kg/m2). Due to
missing data, the total was divided by the
number of available items. Thus, the in-
sulin resistance score ranged from 0 to 1
and was expressed in arbitrary units.
Biological determinations
HbA1c was measured by high-perfor-
mance liquid chromatography (Diamat;
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Biorad, Ivry-sur-Seine, France) (normal
values 4 – 6%). Serum creatinine was
measured using a modified version of
Jaffe’s method. Urinary albumin concen-
tration was determined using a nephelo-
metric method (32) on sterile urine
(verified by dipstick test). Plasma glucose
concentration was determined by using
an enzymatic peroxidase method. Fasting
serum insulin was determined in non–
type 1 diabetic first-degree relatives using
an immunoradiometric assay method (Bi-
Insulin IRMA; Schering, Gif-sur-Yvette,
France), allowing for the calculation of
homeostasis model assessment of insulin
resistance (HOMA-IR) (33).
Statistical analysis
Data are presented as means SD or me-
dian (range), if not normally distributed.
Categorical variables were compared by
using the 2 test and the 2 test for trend
(34). ANOVA and Kruskal-Wallis were
used to compare continuous variables ac-
cording to index microvascular stages in
probands or in relatives. A nonparametric
Spearman test was used for correlation
analyses. To take intrafamilial correla-
tions into account, we used the PROC
MIXED software for continuous variables
and ran generalized estimating equations
as implemented in the PROC GENMOD
software for categorical variables. Stat-
view 5.1 and SAS 8.2 (SAS Institute, Cary,
NC) were used for calculations. Statistical
significance was set at 0.05.
RESULTS— A total of 853 subjects
were recruited in the Genesis France-
Belgium Family Study (578 relatives and
275 probands; 130 probands with and
145 without diabetic nephropathy). Con-
trol families included 120 trios, 22
pseudotrios, and 3 complex families (5 of
306 relatives had type 1 diabetes). Case
fami l i e s inc luded 105 t r ios , 17
pseudotrios, and 8 complex families
(there were 15 subjects with type 1 diabe-
tes among 272 relatives). In total, 269
mothers, 239 fathers, and 70 siblings
were analyzed. The familial structure
(mothers, fathers, siblings) did not differ
between case and control subjects (2 
0.107, P  0.9481).
Microvascular complications in
probands
The characteristics of probands according
to nephropathy stage are summarized in
Table 1. As expected, SBP and the pro-
portion of patients with proliferative reti-
nopathy increased with severity of
nephropathy. BMI did not differ accord-
ing to severity of nephropathy.
The characteristics of probands ac-
cording to their diabetic retinopathy stage
are summarized in Table 2. Systolic blood
pressure differed significantly according
to retinopathy stage. Diabetes duration
was longer in patients with proliferative
retinopathy compared with other sub-
jects. BMI did not differ between groups.
Familial data
Mean age was 70  9, 68  9, and 47 
10 years in fathers, mothers, and siblings,
respectively. Type 2 diabetes was found in
44 subjects. History of arterial hyperten-
sion was found in 200 subjects, and a per-
sonal history of dyslipidemia was found
in 190 relatives. Histories of diabetes and
hypertension were closely related (2 
7.139, P  0.0001), unlike histories of
diabetes and dyslipidemia (2  0.774,
P  0.3488). Myocardial infarction was
found in 39 subjects and was more fre-
quent in relatives with type 2 diabetes
than in nondiabetic relatives (2 7.069,
P  0.0078). In relatives who gave a
blood sample in the fasting state (n 
358), who were not different from non-
fasting relatives regarding age (P 0.89),
insulin resistance score (P  0.57), or
BMI (P  0.69), the insulin resistance
score was positively correlated with fast-
ing insulinemia (  0.109, P 0.0469)
and HOMA-IR (  0.184, P 0.0028).
The insulin resistance score was positively
correlated with HbA1c in relatives ( 
0.284, P  0.0001), even after exclusion
of type 2 diabetic relatives. The insulin
resistance score was also correlated with
urinary albumin excretion (UAE) ( 
0.144, P  0.0009).
UAE was higher in relatives of pro-
band case subjects with incipient, estab-
lished, or advanced diabetic nephropathy
(8 mg/l [2–1,126]) than in relatives of
control subjects without diabetic ne-
phropathy (6 mg/l [2–640], P 0.0176).
The UAE in relatives was not associated
with retinopathy severity in probands
(data not shown).
The clinical and biological character-
istics of first-degree relatives according to
proband nephropathy stage are summa-
rized in Table 3. Insulin resistance scores
were significantly higher in first-degree
relatives of nephropathic (0.37  0.26)
than in those of nonnephropathic (0.31
Table 1—Clinical and biological characteristics according to the severity of diabetic nephropathy in probands
Proband diabetic nephropathy stage
Absent Incipient Established Advanced P
n (%) 145 63 33 34
Sex (M/F) 76/69 27/36 16/17 22/12 0.02196*
Age (years) 41  9 39  8 41  9 42  8 0.1846†
Diabetes duration (years) 26  8 22  8 25  8 27  8 0.0072†
BMI (kg/m2) 24.2  3.2 24.8  4.1 25.2  3.6 23.7  3.5 0.2073†
HbA1c (%) 8.5  1.3 8.6  1.4 8.4  1.2 8.1  1.4 0.4358†
Daily insulin dose (IU  kg body wt1  day1) 0.69  0.20 0.76  0.27 0.66  0.26 0.64  0.22 0.0380‡
SBP (mmHg) 126  17 131  19 134  20 155  26 0.0001†
DBP (mmHg) 73  9 76  11 79  10 85  12 0.0001†
Serum creatinine (mol/l) 78 (46–116) 79 (42–106) 98 (52–149) 212 (150–832) 0.0001‡
Retinopathy stage (1/2/3) 82/29/34 25/16/22 7/5/21 1/6/27 0.0001*
Data are means SD or median (range). *2 test, †ANOVA, ‡Kruskal-Wallis test. Retinopathy stages are 1 (background)/2 (preproliferative)/3 (proliferative). DBP,
diastolic blood pressure.
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0.25, P  0.0370) probands. The fre-
quency of lipid disorders in relatives in-
creased with the nephropathy stage of the
proband. No such relationship was found
with regard to history of type 2 diabetes or
hypertension when fathers and mothers
were analyzed separately. SBP and BMI
did not differ in relatives according to the
nephropathy stage of the proband (F 
0.956, P  0.4132 and F  1.676, P 
0.1710, respectively). However, maternal
SBP increased with the severity of diabetic
nephropathy in type 1 diabetic offspring
(F  3.836, P  0.0104). Systolic blood
pressure was higher in mothers of ne-
phropathic (137 17 mmHg) than non-
nephropathic (132  14 mmHg, P 
0.0071) probands.
The clinical and biological character-
istics of relatives according to proband
retinopathy stage are summarized in Ta-
ble 4. The insulin resistance scores of rel-
atives depended on retinopathy severity.
The insulin resistance scores of relatives
of probands with proliferative retinopa-
thy was significantly higher compared
with relatives of probands without prolif-
erative retinopathy (P 0.0144). Taking
nephropathy into account did not sub-
stantially modify the relationship (P 
0.0379). The frequency of type 2 diabetes
did not depend on the severity of the ret-
inopathy in the probands when fathers
Table 2—Clinical and biological characteristics according to the severity of diabetic retinopathy in probands
Proband diabetic retinopathy stage
Stage 1 Stage 2 Stage 3 P
n (%) 115 56 104
Sex (M/F) 63/52 33/23 45/59 0.1029*
Age (years) 41  9 42  9 40  8 0.5555†
Diabetes duration (years) 23.8  7.7 24.1  7.7 26.9  8.3 0.0112†
BMI (kg/m2) 24.7  3.6 24.6  3.5 23.9  3.4 0.2446†
HbA1c (%) 8.3  1.2 8.7  1.5 8.4  1.4 0.1968†
Daily insulin dose (IU  kg body wt1  day1) 0.71  0.21 0.76  0.26 0.66  0.22 0.0335‡
SBP (mmHg) 127  20 136  20 135  22 0.0132†
DBP (mmHg) 75  10 77  11 77  11 0.4300†
Serum creatinine (mol/l) 79 (18–172) 74 (28–846) 96 (37–902) 0.0001‡
Diabetic nephropathy stage (abs/inc/est/adv) 82/25/7/1 29/16/5/6 34/22/21/27 0.0001*
Data are means  SD or median (range). *2 test, †ANOVA, ‡Kruskal-Wallis test. Diabetic retinopathy stages 1, 2, and 3 are background, preproliferative, and
proliferative, respectively. Diabetic nephropathy stages are abs (absent)/inc (incipent)/est (established)/adv (advanced). DBP, diastolic blood pressure.
Table 3—Insulin resistance components in first-degree relatives according to probands nephropathy stage
Probands diabetic nephropathy stage
Absent Incipient Established Advanced P
n (relatives) 306 126 74 72
Sex (M/F) 139/167 62/64 35/39 32/40 0.8848
Age (years) 66  11 66  12 64  13 65  12 0.2632*
Personal history of type 2 diabetes (present/absent) 22/275 10/109 7/64 5/62 0.0001†
Personal history of hypertension (present/absent) 99/195 46/75 31/37 25/41 0.0655†
Personal history of dyslipidemia (present/absent) 87/204 42/74 30/38 22/37 0.0070†
Obesity status (NW/OW/Ob) 133/108/52 56/49/20 27/25/19 24/29/18 0.0001†
Insulin resistance score 0.31  0.25 0.33  0.26 0.39  0.27 0.35  0.25 0.04‡
n (fathers) 123 58 26 26
Personal history of type 2 diabetes (present/absent) 13/111 4/51 3/24 4/22 0.5793§
Personal history of hypertension (present/absent) 47/77 22/34 13/13 12/13 0.1201§
Personal history of dyslipidemia (present/absent) 38/85 19/35 13/14 7/15 0.3469§
Obesity status (NW/OW/Ob) 46/50/27 21/29/8 8/9/9 7/14/5 0.4029§
Insulin resistance score 0.37  0.26 0.33  0.25 0.45  0.27 0.37  0.22 0.2907*
n (mothers) 134 61 31 32
Personal history of type 2 diabetes (present/absent) 6/136 6/53 3/27 1/30 0.6131§
Personal history of hypertension (present/absent) 49/99 24/36 15/14 12/19 0.2211§
Personal history of dyslipidemia (present/absent) 45/92 22/35 15/15 13/17 0.0062§
Obesity status (NW/OW/Ob) 67/45/23 30/19/12 12/12/7 9/11/12 0.0077§
Insulin resistance score 0.29  0.24 0.36  0.26 0.43  0.26 0.38  0.27 0.0204*
Data are means SD or median (range). *ANOVA, †PROC GENMOD analysis, ‡PROC MIXED analysis, §2 for trend test. Obesity status: NW, normal weight (BMI
25 kg/m2)/OW, overweight (BMI 25–29.9 kg/m2)/Ob, obese (BMI 30 kg/m2).
Family insulin resistance and microangiopathy
2664 DIABETES CARE, VOLUME 27, NUMBER 11, NOVEMBER 2004
and mothers were analyzed separately.
However, the frequencies of obesity and
hypertension in the relatives increased
significantly with the severity of diabetic
retinopathy in the probands. Systolic
blood pressure was not related to the se-
verity of retinopathy in the probands even
when considering mothers or fathers sep-
arately (data not shown).
CONCLUSIONS— In this large fam-
ily-based study, we found that the insulin
resistance score was higher in first-degree
relatives of probands with rather than
without nephropathy. Interestingly, it
was also higher in first-degree relatives of
probands with severe retinopathy, even
after controlling for nephropathy. We
found that arterial hypertension and obe-
sity segregated with retinopathy, whereas
lipid disorders and obesity segregated
with nephropathy. These results were
particularly relevant in mothers of type 1
probands.
This study does, however, have some
limitations. Hypertension in relatives was
diagnosed by using a questionnaire and
by recording blood pressure on just one
occasion. Furthermore, we did not mea-
sure serum lipids; instead, we used a
structured questionnaire to interview rel-
atives. Moreover, we were not able to
measure insulin resistance with the refer-
ence euglycemic clamp technique due to a
very large number of relatives. We were
also unfortunately not able to consider
waist and hip circumferences. However,
we found that insulin resistance was pos-
itively correlated with fasting insuline-
mia, HOMA-IR, and HbA1c, strongly
suggesting that this score effectively re-
flects insulin resistance, as recently sug-
gested (35). A relationship was also found
between the insulin resistance score and
UAE, as proposed in the WHO working
definition (16) and as shown in Finnish
patients (36).
The characteristics of our study pop-
ulation were in good accordance with
previous studies. In probands, blood
pressure significantly increased with the
severity of nephropathy (29). Diabetes
duration was a major risk factor for severe
diabetic retinopathy (37,38). The preva-
lence of hypertension, lipid disorders,
and type 2 diabetes in relatives was in
good accordance with data from the
French general population (39,40). The
sample frequency of case and control pro-
bands is very similar to what was expected
from the general population (36).
We found that insulin resistance was
higher in relatives of proband case sub-
jects with nephropathy than in those of
control subjects without nephropathy.
This is in good accordance with three
previous studies (26–28) showing that
relatives of microalbuminuric or nephro-
pathic patients are more resistant to insu-
lin than relatives of normoalbuminuric
patients, using the euglycemic clamp ref-
erence or other surrogate methods.
Our results extend our knowledge,
showing that familial insulin resistance, in
addition to nephropathy, is also related to
retinopathy. This relationship between
familial insulin resistance and the pres-
ence of microvascular complications in
index type 1 diabetic subjects is in good
accordance with the data from prospec-
tive follow-up studies (24,25), showing
that insulin resistance is a risk factor for
progression or development of retinopa-
thy or nephropathy in type 1 diabetic pa-
tients. This report is the first to
demonstrate an association between fa-
milial insulin resistance and the severity
of retinopathy in diabetic first-degree
relatives.
Our data support the hypothesis that
insulin resistance has a familial compo-
nent that affects the risk of microvascular
disease. This is in good accordance with
Table 4—Insulin resistance components in first-degree relatives according to probands retinopathy stage
Probands diabetic retinopathy stage
Stage 1 Stage 2 Stage 3 P
n (relatives) 246 114 218
Sex (M/F) 111/135 55/59 102/116 0.8476
Age (years) 66  12 66  12 66  12 0.8778*
Personal history of type 2 diabetes (present/absent) 20/214 5/107 19/189 0.0001†
Personal history of hypertension (present/absent) 78/156 37/73 86/119 0.0002†
Personal history of dyslipidemia (present/absent) 69/161 42/67 70/125 0.0001†
Obesity status (NW/OW/Ob) 112/84/39 45/46/21 83/81/49 0.0001†
Insulin resistance score 0.31  0.25 0.31  0.26 0.37  0.25 0.06‡
n (fathers) 97 48 88
Personal history of type 2 diabetes (present/absent) 12/84 3/46 9/78 0.6159§
Personal history of hypertension (present/absent) 35/60 20/29 39/49 0.2743§
Personal history of dyslipidemia (present/absent) 34/62 18/30 26/56 0.6174§
Obesity status (NW/OW/Ob) 38/39/20 16/23/9 28/40/20 0.3832§
Insulin resistance score 0.38  0.26 0.34  0.27 0.38  0.25 0.6834*
n (mothers) 106 53 99
Personal history of type 2 diabetes (present/absent) 6/104 1/52 9/90 0.2892§
Personal history of hypertension (present/absent) 39/72 16/36 45/52 0.1047§
Personal history of dyslipidemia (present/absent) 32/75 21/30 42/54 0.0408§
Obesity status (NW/OW/Ob) 55/34/17 23/19/11 40/34/26 0.0433§
Insulin resistance score 0.29  0.23 0.32  0.26 0.39  0.26 0.0084*
Data are means SD or median (range). *ANOVA, †PROC GENMOD analysis, ‡PROC MIXED analysis, §2 for trend test. Obesity status: NW, normal weight (BMI
25 kg/m2)/OW, overweight (BMI 25–29.9 kg/m2)/Ob, obese (BMI 30 kg/m2).
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the results from studies showing an in-
creased risk of microangiopathy in dia-
betic patients that carry the genetic
variants associated with insulin resistance
in peroxisome proliferator–activated re-
ceptor-	 (41) or human glycoprotein
PC-1 genes (42). However, insulin resis-
tance syndrome is an intermediate pheno-
type with both genetic and environmental
components. We therefore cannot infer
from our data that the genetic compo-
nents of risk for microangiopathy in type
1 diabetic subjects are due to the genetic
components of insulin resistance. In-
stead, we can conclude that discrete com-
ponents of the insulin resistance
syndrome segregate with discrete mani-
festations of diabetic microangiopathy.
We evidenced an association between
history of hypertension in relatives and
diabetic nephropathy, as shown in some
(8,9) but not all (43) previous reports. We
found that mothers of nephropathic pro-
bands had higher SBP values than moth-
ers of control subjects. This discrepancy
for fathers may be related to the insuffi-
cient sensitivity of the office blood pres-
sure measurement apparatus , as
suggested by a Finnish study (10). Con-
sistent with the possibility, the relatives of
probands with nephropathy (incipient to
advanced) displayed higher UAE than
those of control subjects. Some candidate
genes could explain the association be-
tween familial hypertension and retinop-
athy, such as endothelial nitric oxide
synthase (44).
Personal history of dyslipidemia was
slightly more frequent among relatives of
index case subjects than others. This re-
port confirms the data from a single-
center family-based study showing a
clustering of dyslipidemia with nephrop-
athy (28). Familial clustering of lipid dis-
turbances may partly account for the
reported familial clustering of cardiovas-
cular disease in type 1 diabetic patients
with nephropathy (6,7,28,45). Lipid dis-
turbances are well known to be associated
with diabetic nephropathy (46,47), and
prospective studies of type 1 diabetic pa-
tients have shown that an adverse lipid
profile is predictive of the worsening of
renal disease (18,48) or the least regres-
sion from microalbuminuria to nor-
moalbuminuria (49). The adverse role of
plasma lipids was recently found regard-
ing renal and retinal complications in a
longitudinal study (50). Several candidate
genes involved in lipid metabolism could
account for the relationship between fa-
milial lipid disorders and nephropathy,
with apolipoprotein E being already
widely studied (47,51,52).
Obesity in relatives was strongly asso-
ciated with the risk of both severe retinop-
athy and nephropathy. This is in good
accordance with previous reports show-
ing that BMI was higher in type 1 diabetic
patients who developed retinopathy (21)
or nephropathy (24). Interestingly, the
role of obesity in patients is not due to a
familial resemblance, as BMI did not dif-
fer according to nephropathy or retinop-
athy stage of the index patients.
Candidate genes for obesity are currently
extensively studied, and some of them,
such as adiponectin (53), could be asso-
ciated with microvascular complications,
as suggested by our results.
In conclusion, first-degree relatives
are more insulin resistant when type 1 di-
abetic probands have more severe dia-
betic retinopathy or nephropathy. The
components of the insulin resistance syn-
drome support the search for genetic fac-
tors involved in arterial hypertension and
obesity for retinopathy and in lipids and
obesity for nephropathy.
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